Moxidectin versus ivermectin for strongyloidiasis control

Lancet Infect Dis. 2024 Mar;24(3):e152. doi: 10.1016/S1473-3099(23)00823-X. Epub 2024 Jan 15.

Authors

Javier Gandasegui¹, José Muñoz², Pedro Fleitas², Cristina Mazzi³, Zeno Bisoffi³

Affiliations

¹ Barcelona Institute for Global Health, Hospital Clínic-Universitat de Barcelona, Barcelona, 08036, Spain. Electronic address: javier.gandasegui@isglobal.org.
² Barcelona Institute for Global Health, Hospital Clínic-Universitat de Barcelona, Barcelona, 08036, Spain.
³ IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.

PMID: 38237614
DOI: 10.1016/S1473-3099(23)00823-X

No abstract available

Publication types

Letter

MeSH terms

Anthelmintics* / therapeutic use
Humans
Ivermectin / therapeutic use
Macrolides / therapeutic use
Strongyloidiasis* / drug therapy
Strongyloidiasis* / prevention & control

Substances

Ivermectin
moxidectin
Macrolides
Anthelmintics